Alirocumab: Revision history

18 July 2021

• curprev 03:2103:21, 18 July 2021‎ Aysha Aslam talk contribs‎ 69,956 bytes +1‎ No edit summary

28 December 2016

• curprev 20:3620:36, 28 December 2016‎ Tarek Nafee talk contribs‎ 69,955 bytes +2,201‎ →‎Future Investigations Tag: Visual edit
• curprev 20:0420:04, 28 December 2016‎ Tarek Nafee talk contribs‎ 67,754 bytes +835‎ →‎ODYSSEY - ESCAPE Tag: Visual edit
• curprev 19:3619:36, 28 December 2016‎ Tarek Nafee talk contribs‎ 66,919 bytes −12‎ →‎Cost-Effectiveness
• curprev 19:3419:34, 28 December 2016‎ Tarek Nafee talk contribs‎ 66,931 bytes −20‎ →‎Drug Packaging and Label
• curprev 19:3219:32, 28 December 2016‎ Tarek Nafee talk contribs‎ 66,951 bytes +81‎ →‎Clinical Studies Tag: Visual edit
• curprev 19:2519:25, 28 December 2016‎ Tarek Nafee talk contribs‎ 66,870 bytes +15‎ →‎Clinical Studies
• curprev 19:2019:20, 28 December 2016‎ Tarek Nafee talk contribs‎ 66,855 bytes +8,675‎ →‎Clinical Trials Experience Tag: Visual edit
• curprev 19:1119:11, 28 December 2016‎ Tarek Nafee talk contribs‎ 58,180 bytes −724‎ →‎Adverse Reactions
• curprev 19:0819:08, 28 December 2016‎ Tarek Nafee talk contribs‎ 58,904 bytes −4‎ No edit summary Tag: Visual edit
• curprev 19:0719:07, 28 December 2016‎ Tarek Nafee talk contribs‎ 58,908 bytes +37‎ →‎Patient Counseling Information

27 December 2016

• curprev 23:1923:19, 27 December 2016‎ Tarek Nafee talk contribs‎ 58,871 bytes +6‎ →‎How Supplied/Storage and Handling Tag: Visual edit
• curprev 23:1523:15, 27 December 2016‎ Tarek Nafee talk contribs‎ 58,865 bytes +49‎ →‎Drug Packaging and Label
• curprev 23:1423:14, 27 December 2016‎ Tarek Nafee talk contribs‎ 58,816 bytes +88‎ →‎Images
• curprev 23:1323:13, 27 December 2016‎ Tarek Nafee talk contribs‎ 58,728 bytes +2,204‎ →‎Non Clinical Toxicology Tag: Visual edit
• curprev 23:0923:09, 27 December 2016‎ Tarek Nafee talk contribs‎ 56,524 bytes −2,512‎ No edit summary Tag: Visual edit
• curprev 23:0823:08, 27 December 2016‎ Tarek Nafee talk contribs‎ 59,036 bytes +2,512‎ No edit summary Tag: Visual edit
• curprev 22:5622:56, 27 December 2016‎ Tarek Nafee talk contribs‎ 56,524 bytes +17,619‎ No edit summary Tag: Visual edit
• curprev 22:2322:23, 27 December 2016‎ Tarek Nafee talk contribs‎ 38,905 bytes +614‎ →‎Disclaimer
• curprev 22:0022:00, 27 December 2016‎ Tarek Nafee talk contribs‎ 38,291 bytes +701‎ No edit summary Tag: Visual edit
• curprev 21:5521:55, 27 December 2016‎ Tarek Nafee talk contribs‎ 37,590 bytes +27‎ →‎Synopsis

22 December 2016

• curprev 00:0700:07, 22 December 2016‎ Tarek Nafee talk contribs‎ 37,563 bytes +5‎ No edit summary
• curprev 00:0700:07, 22 December 2016‎ Tarek Nafee talk contribs‎ 37,558 bytes −68‎ →‎Approved Indications
• curprev 00:0600:06, 22 December 2016‎ Tarek Nafee talk contribs‎ 37,626 bytes −41‎ →‎Investigational Indications
• curprev 00:0300:03, 22 December 2016‎ Tarek Nafee talk contribs‎ 37,667 bytes +3,041‎ →‎ODYSSEY - CHOICE I Tag: Visual edit

21 December 2016

• curprev 22:0922:09, 21 December 2016‎ Tarek Nafee talk contribs‎ 34,626 bytes −27‎ →‎Major Trials

20 December 2016

• curprev 01:2801:28, 20 December 2016‎ Tarek Nafee talk contribs‎ 34,653 bytes +6,327‎ →‎ODYSSEY -ALTERNATIVE Tag: Visual edit

19 December 2016

• curprev 21:1621:16, 19 December 2016‎ Tarek Nafee talk contribs‎ 28,326 bytes +866‎ →‎Phase III Trials
• curprev 15:5615:56, 19 December 2016‎ Tarek Nafee talk contribs‎ 27,460 bytes +32‎ →‎Synopsis

15 December 2016

• curprev 21:2921:29, 15 December 2016‎ Tarek Nafee talk contribs‎ 27,428 bytes +309‎ →‎Phase III Trials Tag: Visual edit
• curprev 21:1121:11, 15 December 2016‎ Aysha Aslam talk contribs‎ 27,119 bytes −3‎ →‎Investigational Indications Tag: Visual edit
• curprev 21:1121:11, 15 December 2016‎ Aysha Aslam talk contribs‎ 27,122 bytes +3‎ →‎Investigational Indications
• curprev 21:1021:10, 15 December 2016‎ Aysha Aslam talk contribs‎ 27,119 bytes −3‎ →‎Investigational Indications
• curprev 21:1021:10, 15 December 2016‎ Aysha Aslam talk contribs‎ 27,122 bytes +127‎ →‎Investigational Indications Tag: Visual edit
• curprev 20:0420:04, 15 December 2016‎ Aysha Aslam talk contribs‎ 26,995 bytes +1‎ No edit summary
• curprev 20:0420:04, 15 December 2016‎ Aysha Aslam talk contribs‎ 26,994 bytes +6‎ No edit summary
• curprev 20:0120:01, 15 December 2016‎ Aysha Aslam talk contribs‎ 26,988 bytes +418‎ →‎Contraindications Tag: Visual edit
• curprev 19:1419:14, 15 December 2016‎ Tarek Nafee talk contribs‎ 26,570 bytes +2,304‎ →‎Major Trials Tag: Visual edit
• curprev 17:0717:07, 15 December 2016‎ Tarek Nafee talk contribs‎ 24,266 bytes +1,026‎ No edit summary Tag: Visual edit
• curprev 14:5914:59, 15 December 2016‎ Aysha Aslam talk contribs‎ 23,240 bytes +376‎ →‎Synopsis Tag: Visual edit
• curprev 00:1500:15, 15 December 2016‎ Tarek Nafee talk contribs‎ 22,864 bytes +295‎ No edit summary Tag: Visual edit

14 December 2016

• curprev 23:4123:41, 14 December 2016‎ Tarek Nafee talk contribs‎ 22,569 bytes +2,410‎ No edit summary Tag: Visual edit
• curprev 21:4921:49, 14 December 2016‎ Tarek Nafee talk contribs‎ 20,159 bytes +2,207‎ No edit summary Tag: Visual edit
• curprev 20:1820:18, 14 December 2016‎ Tarek Nafee talk contribs‎ 17,952 bytes +1,408‎ No edit summary Tag: Visual edit
• curprev 19:0319:03, 14 December 2016‎ Tarek Nafee talk contribs‎ 16,544 bytes +1,444‎ →‎Major Trials Tag: Visual edit
• curprev 16:5516:55, 14 December 2016‎ Tarek Nafee talk contribs‎ 15,100 bytes +15‎ No edit summary
• curprev 16:5416:54, 14 December 2016‎ Tarek Nafee talk contribs‎ 15,085 bytes +686‎ →‎Major Trials Tag: Visual edit

13 December 2016

• curprev 23:2823:28, 13 December 2016‎ Tarek Nafee talk contribs‎ 14,399 bytes +5‎ →‎Synopsis Tag: Visual edit
• curprev 23:2823:28, 13 December 2016‎ Aysha Aslam talk contribs‎ 14,394 bytes +354‎ →‎Synopsis Tag: Visual edit
• curprev 20:5620:56, 13 December 2016‎ Tarek Nafee talk contribs‎ 14,040 bytes +740‎ →‎Synopsis Tag: Visual edit
• curprev 19:4119:41, 13 December 2016‎ Tarek Nafee talk contribs‎ 13,300 bytes +1,238‎ No edit summary Tag: Visual edit

18 August 2015

• curprev 22:1322:13, 18 August 2015‎ Becca Cohen talk contribs‎ 12,062 bytes +2,225‎ No edit summary

24 March 2015

• curprev 15:5915:59, 24 March 2015‎ Sergekorjian talk contribs‎ 9,837 bytes +1,305‎ →‎ODYSSEY - Long Term
• curprev 15:4315:43, 24 March 2015‎ Sergekorjian talk contribs‎ 8,532 bytes −26‎ →‎ODYSSEY - FH II
• curprev 15:4315:43, 24 March 2015‎ Sergekorjian talk contribs‎ 8,558 bytes +673‎ →‎ODYSSEY - FH I
• curprev 15:2615:26, 24 March 2015‎ Sergekorjian talk contribs‎ 7,885 bytes −28‎ →‎ODYSSEY - COMBO I
• curprev 15:2015:20, 24 March 2015‎ Sergekorjian talk contribs‎ 7,913 bytes +601‎ →‎ODYSSEY - COMBO II
• curprev 15:1915:19, 24 March 2015‎ Sergekorjian talk contribs‎ 7,312 bytes +777‎ →‎ODYSSEY - COMBO II

19 March 2015

• curprev 16:0116:01, 19 March 2015‎ Sergekorjian talk contribs‎ 6,535 bytes +138‎ →‎Phase III Trials
• curprev 15:5515:55, 19 March 2015‎ Sergekorjian talk contribs‎ 6,397 bytes 0‎ →‎Phase II Trials
• curprev 15:4415:44, 19 March 2015‎ Sergekorjian talk contribs‎ 6,397 bytes +1,326‎ →‎Safety and efficacy of atorvastatin with or without alirocumab in primary hypercholesterolemia (NCT 01288469)
• curprev 15:3415:34, 19 March 2015‎ Sergekorjian talk contribs‎ 5,071 bytes +15‎ →‎Safety and efficacy of atorvastatin with or without alirocumab in primary hypercholesterolemia
• curprev 15:3415:34, 19 March 2015‎ Sergekorjian talk contribs‎ 5,056 bytes +15‎ →‎Safety and efficacy in primary hypercholesterolemia with ongoing stable atorvastatin therapy
• curprev 15:3315:33, 19 March 2015‎ Sergekorjian talk contribs‎ 5,041 bytes +15‎ →‎Safety and efficacy in heterozygous familial hypercholesterolaemia with ongoing stable-dose statin with or without ezetimibe therapy
• curprev 15:3115:31, 19 March 2015‎ Sergekorjian talk contribs‎ 5,026 bytes +106‎ →‎Phase II Trials
• curprev 15:2815:28, 19 March 2015‎ Sergekorjian talk contribs‎ 4,920 bytes +13‎ →‎Safety and efficacy in heterozygous familial hypercholesterolaemia with ongoing stable-dose statin with or without ezetimibe therapy
• curprev 15:2815:28, 19 March 2015‎ Sergekorjian talk contribs‎ 4,907 bytes +1,724‎ →‎Phase II Trials
• curprev 15:1415:14, 19 March 2015‎ Sergekorjian talk contribs‎ 3,183 bytes +1,338‎ →‎Safety and efficacy in primary hypercholesterolemia with ongoing stable atorvastatin therapy
• curprev 13:3913:39, 19 March 2015‎ Sergekorjian talk contribs‎ 1,845 bytes +103‎ →‎Phase II Trials
• curprev 13:3113:31, 19 March 2015‎ Sergekorjian talk contribs‎ 1,742 bytes +638‎ →‎Properties
• curprev 13:2413:24, 19 March 2015‎ Sergekorjian talk contribs‎ 1,104 bytes +146‎ →‎Overview

10 November 2014

• curprev 16:4216:42, 10 November 2014‎ Sergekorjian talk contribs‎ 958 bytes +7‎ Undo revision 1040125 by Sergekorjian (talk)
• curprev 16:4116:41, 10 November 2014‎ Sergekorjian talk contribs‎ 951 bytes −7‎ No edit summary

29 September 2014

• curprev 20:0720:07, 29 September 2014‎ Sergekorjian talk contribs‎ 958 bytes +958‎ Created page with "__NOTOC__ File:Pharmacologic-interventions-for-PCSK9.jpg|250px|thumb|right|Pharmacologic interventions for PCSK9 <font size="1">''Adapted from Journal of the American Colle..."